Seatbelts in CAR therapy: How safe are CARS?

Academic Article


  • T-cells genetically redirected with a chimeric antigen receptor (CAR) to recognize tumor antigens and kill tumor cells have been infused in several phase 1 clinical trials with success. Due to safety concerns related to on-target/off-tumor effects or cytokine release syndrome, however, strategies to prevent or abate serious adverse events are required. Pharmacologic therapies; suicide genes; or novel strategies to limit the cytotoxic effect only to malignant cells are under active investigations. In this review, we summarize results and toxicities of investigations employing CAR redirected T-cells, with a focus on published strategies to grant safety of this promising cellular application.
  • Published In

  • Pharmaceuticals  Journal
  • Digital Object Identifier (doi)

    Author List

  • Minagawa K; Zhou X; Mineishi S; Di Stasi A
  • Start Page

  • 230
  • End Page

  • 249
  • Volume

  • 8
  • Issue

  • 2